Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
hCG, H3K27 Methylation, and CXCL10 in Decidua
2026-10-01
The reference study defines a chromatin-based mechanism by which trophoblast-derived human chorionic gonadotropin suppresses CXCL10 in human decidual stromal cells. Its central contribution is linking hCG, EZH2-dependent H3K27me3 deposition, reduced CD8-cell recruitment, and immune regulation at the maternal–fetal interface.
-
GSK J4 HCl: JMJD3 Workflow and Applications
2026-10-01
GSK J4 HCl supports mechanism-first studies that connect JMJD3 activity with H3K27 methylation, cytokine output, and tumor biology. This guide translates the decidual CXCL10 study into practical chromatin, inflammation, and glioma workflows while emphasizing controls and troubleshooting.
-
EPZ5676: DOT1L Inhibitor Workflow Guide
2026-09-30
Build a mechanism-led workflow around EPZ5676 for DOT1L activity profiling, H3K79 methylation inhibition, and MLL-rearranged leukemia models. This guide connects biochemical assays with cellular validation while emphasizing solvent control, SAM competition, orthogonal readouts, and practical troubleshooting.
-
RESTRICT-seq Maps Epigenetic SCC Resistance
2026-09-30
The preprint introduces RESTRICT-seq, a time-gated CRISPR screening strategy designed to distinguish epigenetic dependencies that arise during squamous cell carcinoma resistance from vulnerabilities present before resistance develops. Its main contribution is methodological: aligning genetic perturbation with disease-state timing provides a more informative framework for discovering resistance-associated dependencies and prioritizing follow-up experiments.
-
Rocilinostat (ACY-1215): Workflow Guide
2026-09-29
Build cleaner HDAC6-centered experiments with Rocilinostat (ACY-1215), from α-tubulin acetylation and multiple myeloma cell viability assays to proteasome-inhibitor combination studies. A separate neurodevelopment application shows how the compound can support carefully bounded cilia and neural-progenitor hypotheses without overstating cross-domain evidence.
-
Tiamulin Workflows for Veterinary Research
2026-09-29
Tiamulin (Thiamutilin) combines pleuromutilin antibacterial activity with investigational anti-inflammatory effects, making it useful for susceptibility, cell-signaling, and pharmacokinetic workflows. This guide translates those properties into practical assay design, formulation controls, PK/PD interpretation, and troubleshooting for veterinary research.
-
hCG–EZH2–CXCL10 Signaling in Human Decidua
2026-09-28
The reference study shows that human chorionic gonadotropin suppresses CXCL10 in human decidual stromal cells through EZH2-dependent deposition of the repressive H3K27me3 mark. By connecting hormone signaling, promoter-localized chromatin remodeling, and CD8-cell recruitment, the work provides a mechanistic framework for understanding immune regulation at the maternal–fetal interface.
-
From SIRT1 Biology to Bone-Regeneration Strategy
2026-09-28
A translational perspective on how SIRT1 links vascular and osteogenic function in aging bone—and how researchers can rigorously evaluate SRT1720 HCl as a tool for testing that biology.
-
SP2509 and LSD1: Interpreting Epigenetic Dependencies
2026-09-27
SP2509 is a potent Lysine-specific demethylase 1 antagonist for studying how LSD1-linked chromatin regulation shapes cancer-cell states. This article connects its AML evidence to a breast-cancer study of BRD4–RAC1 co-targeting while clarifying what that cross-domain comparison can—and cannot—tell researchers.
-
Dual-SMAD and Wnt Inhibition for iPSC-Derived RGCs
2026-09-26
The study presents a chemically defined strategy combining SMAD-pathway and canonical Wnt inhibition to generate retinal ganglion cells from induced pluripotent stem cells with improved efficiency and reproducibility. The workflow produced cultures reported to exceed 80% RGC purity and enabled further enrichment to nearly 95%, offering a practical platform for retinal disease modeling while leaving questions of long-term function and therapeutic use open.
-
Engineering T-Cell Immunity in Immune-Cold Tumors
2026-09-25
He et al. describe a tumor-targeted plasmid that combines LIGHT-mediated immune recruitment and tissue remodeling with tumor-localized anti-CD3 T-cell engagement. In preclinical solid-tumor settings, this coordinated strategy increased antitumor T-cell activity and enhanced checkpoint blockade and CAR-T therapy, while its clinical safety and transferability remain to be established.
-
Mouse Toxicology of 5-Aza-2'-deoxycytidine
2026-09-25
Momparler and Frith characterized the acute and recovery-phase toxicity of intravenously infused 5-Aza-2'-deoxycytidine in mice, reporting sex-specific LD50 estimates alongside hematologic and tissue effects. The study’s practical contribution is a preclinical safety profile that cautions against treating antileukemic activity and dose-related toxicity as separable when designing Decitabine experiments.
-
JWH 133 and Liver Iron Overload Mechanisms
2026-09-24
Explore how JWH 133 helps investigate cannabinoid receptor 2 signaling in iron-overloaded liver models. This article connects cell-specific hepcidin and ferroportin mechanisms to practical assay design and the limits of current evidence.
-
LTI6426 Sensitizes Myeloma Models to Panobinostat
2026-09-24
A preclinical study found that inhibiting protein disulfide isomerase with LTI6426 enhanced low-dose panobinostat activity in proteasome inhibitor-resistant multiple myeloma models. The combination induced an endoplasmic-reticulum-stress-associated transcriptional response, identifying ATF3, DDIT3/CHOP, and DNAJB1 as candidate pharmacodynamic biomarkers—not yet clinically validated markers.
-
Propranolol Reprograms Burn-Associated Metabolism
2026-09-23
A phase II randomized study examined how propranolol reshapes adipose-tissue metabolism after severe burns. Its metabolomic and lipidomic findings connect beta-blockade with altered energy and nucleotide pathways, a less inflammatory lipid profile, and reduced markers of lipolysis and endoplasmic-reticulum stress.